The stock of Werewolf Therapeutics Inc (NASDAQ: HOWL) has increased by 13.33 when compared to last closing price of 1.20.Despite this, the company has seen a gain of 14.29% in its stock price over the last five trading days. zacks.com reported 2025-05-29 that Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Werewolf Therapeutics Inc (NASDAQ: HOWL) Right Now?
The stock has a 36-month beta value of 0.66. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HOWL is 33.12M, and at present, short sellers hold a 6.71% of that float. On June 04, 2025, the average trading volume of HOWL was 373.15K shares.
HOWL’s Market Performance
The stock of Werewolf Therapeutics Inc (HOWL) has seen a 14.29% increase in the past week, with a 50.33% rise in the past month, and a 16.24% gain in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 7.14% for HOWL. The simple moving average for the past 20 days is 24.71% for HOWL’s stock, with a -15.04% simple moving average for the past 200 days.
Analysts’ Opinion of HOWL
Many brokerage firms have already submitted their reports for HOWL stocks, with JMP Securities repeating the rating for HOWL by listing it as a “Mkt Outperform.” The predicted price for HOWL in the upcoming period, according to JMP Securities is $12 based on the research report published on April 03, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see HOWL reach a price target of $9. The rating they have provided for HOWL stocks is “Outperform” according to the report published on August 24th, 2023.
Jefferies gave a rating of “Buy” to HOWL, setting the target price at $12 in the report published on June 06th of the previous year.
HOWL Trading at 42.31% from the 50-Day Moving Average
After a stumble in the market that brought HOWL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.25% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOWL starting from RA CAPITAL MANAGEMENT, L.P., who purchase 320,913 shares at the price of $0.86 back on May 12 ’25. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 6,021,969 shares of Werewolf Therapeutics Inc, valued at $275,985 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the Director of Werewolf Therapeutics Inc, purchase 162,539 shares at $0.98 during a trade that took place back on May 14 ’25, which means that RA CAPITAL MANAGEMENT, L.P. is holding 6,237,482 shares at $159,288 based on the most recent closing price.
Stock Fundamentals for HOWL
Current profitability levels for the company are sitting at:
- -49.37 for the present operating margin
- 0.6 for the gross margin
The net margin for Werewolf Therapeutics Inc stands at -63.35. The total capital return value is set at -0.59. Equity return is now at value -82.81, with -50.84 for asset returns.
Based on Werewolf Therapeutics Inc (HOWL), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -5.74. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -23.61.
Currently, EBITDA for the company is -64.05 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of -18.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.09.
Conclusion
To sum up, Werewolf Therapeutics Inc (HOWL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
